Effects of kallikrein on the male reproductive system and its use in the treatment of idiopathic oligozoospermia with impaired motility.
A single-blind study on the effects of kallikrein in idiopathic oligozoospermia was carried out. 8 of the 16 patients admitted to the trial were treated with kallikrein 100 K.U. t.i.d., the remaining patients received vitamin E 100 mg t.i.d. Treatment lasted 120 days in both groups. Kallikrein led to an increase in sperm concentration, total sperm count and sperm penetration capacity. Patients receiving vitamin E failed to show any improvement. It is postulated that the increase in sperm concentration could be explained by the positive action of kallikrein on spermatogenesis, due to a stimulatory effect of the drug directly on the Sertoli cell function and on the circulation in the vascular system of the testis.
D000818:Animals; D002417:Cattle; D002582:Cervix Mucus; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D008297:Male; D009845:Oligospermia / Q000188:drug therapy*; D013076:Sperm Count; D013081:Sperm Motility / Q000187:drug effects*; D013091:Spermatogenesis / Q000187:drug effects; D013094:Spermatozoa / Q000187:drug effects / Q000502:physiology; D013737:Testis / Q000098:blood supply; D014810:Vitamin E / Q000627:therapeutic use
D014810:Vitamin E; D007610:Kallikreins